What is the recommended management approach for obesity in Asian adults, including lifestyle interventions, pharmacotherapy, and bariatric surgery?

Obesity Management in Asian Adults

Obesity in Asian adults should be diagnosed using lower BMI thresholds (≥23 kg/m² for overweight, ≥25 kg/m² for obesity in most South/Southeast Asian countries) combined with waist circumference measurements (≥80 cm for women, ≥90 cm for men), and management should follow a staged approach that integrates lifestyle modification, pharmacotherapy, and bariatric surgery based on BMI, complications, and treatment response rather than requiring sequential failure of each modality. 1

Diagnostic Criteria Specific to Asian Populations

Asian populations require ethnicity-specific cutoffs because they develop obesity-related complications at lower BMI levels than Western populations:

• BMI ≥23 kg/m² defines overweight in most South/Southeast Asian countries
• BMI ≥25 kg/m² defines obesity (Brunei uses ≥25 kg/m² for overweight)
• Waist circumference: ≥80 cm (women) or ≥90 cm (men) confirms excess abdominal adiposity
• Waist-to-height ratio ≥0.5 identifies adolescents at metabolic risk 1

This lower threshold reflects the distinctive Asian obesity phenotype: excess visceral and ectopic fat accumulation, reduced β-cell reserve, sarcopenic obesity, and heightened cardiometabolic risk at lower BMI values 2. Clinicians must conduct comprehensive assessment including physical examination, patient history, and laboratory tests to identify obesity-related complications even in patients approaching but not meeting these cutoffs 1.

Lifestyle Interventions: Foundation of Care

All patients require behavioral modification regardless of treatment stage—whether attempting dietary change alone, using pharmacotherapy, or post-bariatric surgery 1. The 2023 South/Southeast Asia consensus strongly recommends this as foundational care.

Dietary Approaches

• Hypocaloric balanced diet: 1200-1500 kcal/day for women, 1500-1800 kcal/day for men
• Target modest weight loss of approximately 0.5 kg/week
• Moderate fat reduction (≤30% of total calories) 1

Physical Activity

• Encourage daily opportunities for vigorous activity
• For weight maintenance after loss, often >200 minutes/week is required 3

Behavioral Components

• Address stress, unhealthy sleep habits, social dynamics, and environmental factors concurrently 1
• Intensive behavioral interventions under experienced clinicians for suitable individuals
• Web-, phone-, or tablet-based electronic tools may support lifestyle changes 1
• Family involvement is appropriate, particularly for children—family-based interventions combining face-to-face sessions and social media effectively reduce child adiposity 1

Evaluation Timeline

Evaluate lifestyle intervention effectiveness within 3 months 1. For patients showing minimal weight loss, consider intensifying to supervised intensive dietary interventions, pharmacotherapy, or surgical referral based on BMI and complications.

Pharmacotherapy: When and How

Pharmacotherapy should be considered as adjunct therapy to lifestyle modification for adults with BMI ≥30 kg/m² OR BMI ≥27 kg/m² with at least one obesity-related complication 1. Critically, the 2023 consensus emphasizes that pharmacotherapy or surgery may be considered as initial therapeutic approaches for severe obesity requiring immediate substantial weight reduction—lifestyle change does not always need to be attempted first 1.

Specific Indications for Earlier Pharmacotherapy

Consider pharmacotherapy particularly for patients who:

• Require more urgent weight loss due to severe obesity
• Need greater weight loss to manage inadequately controlled obesity-related complications
• Cannot achieve or maintain adequate weight loss through lifestyle intervention alone 1

Special Considerations

• BMI 25-26.9 kg/m² (in countries defining obesity at BMI ≥25): Pharmacotherapy may be considered case-by-case to ameliorate complications, but only by experienced obesity medicine clinicians with close monitoring 1
• Adolescents: Experienced clinicians may consider pharmacotherapy as adjunct to lifestyle interventions for those with severe obesity and inadequate weight loss 1

Duration and Monitoring

• Choice and duration should respect individual clinical characteristics and country-specific approved labeling 1
• Some medications (semaglutide, liraglutide) don't show maximal benefit until after 6 months, so for patients achieving requisite 5% weight loss, continue treatment and evaluate full response after 12 months on maximally tolerated dose 1
• Long-term use is supported as pharmacotherapy produces greater weight-loss maintenance than lifestyle alone 3

Important Caveat

Do not discontinue effective medications to prevent weight regain—obesity is a chronic, relapsing disease requiring long-term management 4.

Bariatric and Metabolic Surgery

Bariatric surgery may be recommended according to national guidelines, or regional guidelines (IFSO Asia Pacific Chapter, Diabetes Surgery Summit) where national guidance is absent 1. Surgery serves as adjunct therapy to lifestyle modification, with or without pharmacotherapy.

Patient Selection

Surgery is generally recommended for:

• Adults aged 18-69 years meeting BMI criteria
• BMI cut points vary by country but use Asian-specific thresholds
• Poorly controlled type 2 diabetes or other obesity complications factor into surgical decisions 1

Special Populations Requiring Careful Assessment

• Adolescents: Requires detailed multidisciplinary team assessment including pubertal/skeletal maturation and family motivation
• Age ≥70 years: Needs experienced care team evaluation
• Contraindications: Substance use disorders, psychiatric illness limiting adherence, hepatic dysfunction, tobacco smoking 1

Preoperative Requirements

Some patients may be required to lose weight via diet and exercise before the procedure. Wait times can be long even for initial consultation 1.

Postoperative Management

Patients require:

• Multidisciplinary team (surgeon, bariatric physician, dietitian, physiotherapist/exercise physiologist, psychologist/psychiatrist) 1
• Strict diet progression initially, lifelong dietary modification
• Lifelong micronutrient supplementation (thiamin, B12, folate, iron, vitamin D, calcium, vitamins A/E/K, zinc, copper) with pre- and post-surgery screening 3
• Regular monitoring for weight regain, nutrient deficiency, and obesity-related complications 1
• Awareness that oral bioavailability of medications (oral contraceptives, warfarin, antibiotics, antidepressants) may be altered 1

Realistic Expectations

Patients must be counseled that partial weight regain is likely—all supportive care options including pharmacotherapy should be considered to maintain weight close to postsurgical nadir 1. Bariatric surgery typically achieves 25-30% weight loss 3.

Treatment Goals and Monitoring

Weight loss of 5-15% over 6 months represents a realistic short-term goal, followed by long-term weight maintenance 1. However, this target should be adjusted based on clinical goals:

• Type 2 diabetes remission: Unrealistic with <10% weight loss 1
• For medications like semaglutide/liraglutide showing maximal benefit after 6 months, extend evaluation to 12 months 1

Ongoing Assessment Strategy

• Regular reassessment of weight and complications
• Interventions may be intensified or deintensified based on response
• Those reaching treatment targets require ongoing support, sometimes extended treatment to maintain initial weight loss
• For individuals without obesity-related complications, periodic ongoing support is recommended 1

Follow-Up Schedule

Close follow-up ideally every 4-6 weeks enables support for lifestyle changes and addresses adverse effects of medications 3.

Critical Clinical Approach

Initial therapy should be tailored to severity of obesity and obesity-related complications 1. This represents the most controversial recommendation—while minority opinion holds that lifestyle change must always be attempted first, the consensus position allows pharmacotherapy or bariatric referral as initial approaches for severe obesity requiring immediate substantial weight reduction 1.

The algorithmic approach:

1. Screen all adults using Asian-specific BMI/waist circumference cutoffs
2. Assess comprehensively for obesity-related complications, health risks, barriers to treatment
3. Initiate lifestyle modification as foundation
4. Evaluate at 3 months—if minimal weight loss, consider intensification
5. Add pharmacotherapy or refer for surgery based on BMI, complications, and urgency
6. Monitor regularly with close follow-up
7. Maintain long-term treatment recognizing obesity's chronic, relapsing nature

Language and Stigma

Use respectful, non-stigmatizing language at all stages of care across the bodyweight spectrum 1. Lack of family support may foster internalized stigma and create psychological barriers to addressing weight issues 1.